Risk of Prostate and Breast Cancer

i Gu, Fredrick R. Schumacher, Federico Canzian, Naomi E. Allen, Demetrius Albanes, Christine D. Berg, I. Berndt, Heiner Boeing, H. Bas Bueno-de-Mesquita, Julie E. Buring, Nathalie Chabbert-Buffet, en J. Chanock, Françoise Clavel-Chapelon, Vanessa Dumeaux, J. Michael Gaziano, rd L. Giovannucci, Christopher A. Haiman, Susan E. Hankinson, Richard B. Hayes, E. Henderson, David J. Hunter, Robert N. Hoover, Mattias Johansson, Timothy J. Key, Kay-Tee Khaw, nce N. Kolonel, Pagona Lagiou, I-Min Lee, Loic LeMarchand, Eiliv Lund, Jing Ma, arlotte Onland-Moret, Kim Overvad, Laudina Rodriguez, Carlotta Sacerdote, Maria-José Sánchez, . Stampfer, Pär Stattin, Daniel O. Stram, Gilles Thomas, Michael J. Thun, Anne Tjønneland, ios Trichopoulos, Rosario Tumino, Jarmo Virtamo, Stephanie J. Weinstein, Walter C. Willett, ith Yeager, Shumin M. Zhang, Rudolf Kaaks, Elio Riboli, Regina G. Ziegler, and Peter Kraft

[1]  M. Thun,et al.  Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. , 2010, Human molecular genetics.

[2]  W. Willett,et al.  A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. , 2010, Human molecular genetics.

[3]  Ross J. Harris,et al.  Circulating insulin‐like growth factor peptides and prostate cancer risk: A systematic review and meta‐analysis , 2009, International journal of cancer.

[4]  H. Grönberg,et al.  Genetic Variation in the SST Gene and its Receptors in Relation to Circulating Levels of Insulin-Like Growth Factor-I, IGFBP3, and Prostate Cancer Risk , 2009, Cancer Epidemiology Biomarkers & Prevention.

[5]  Jonathan Marchini,et al.  Comparing algorithms for genotype imputation. , 2008, American journal of human genetics.

[6]  François G. Meyer,et al.  Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies , 2008, Annals of Internal Medicine.

[7]  M. Pike,et al.  IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3) , 2008, PloS one.

[8]  Eden R Martin,et al.  A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms , 2008, Genetic epidemiology.

[9]  Julian P T Higgins,et al.  Recent developments in meta‐analysis , 2008, Statistics in medicine.

[10]  H. Grönberg,et al.  Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels. , 2007, The Journal of clinical endocrinology and metabolism.

[11]  R. Hayes,et al.  IGF‐1 and IGFBP‐3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial , 2007, International journal of cancer.

[12]  B. Henderson,et al.  Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. , 2007, The Journal of clinical endocrinology and metabolism.

[13]  G. Colditz,et al.  Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study , 2007, Breast Cancer Research.

[14]  N. Weiss,et al.  Prostate Cancer Risk in Relation to Selected Genetic Polymorphisms in Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-3, and Insulin-like Growth Factor-I Receptor , 2006, Cancer Epidemiology Biomarkers & Prevention.

[15]  A. Howell,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. , 2006, Endocrine-related cancer.

[16]  J. Chang-Claude,et al.  Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study , 2006, British Journal of Cancer.

[17]  Nicholas J Wareham,et al.  IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. , 2006, Human molecular genetics.

[18]  W. Willett,et al.  A candidate gene approach to searching for low-penetrance breast and prostate cancer genes , 2005, Nature Reviews Cancer.

[19]  S. Gabriel,et al.  Efficiency and power in genetic association studies , 2005, Nature Genetics.

[20]  J. Chang-Claude,et al.  Genetic Variation in the Growth Hormone Synthesis Pathway in Relation to Circulating Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Breast Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition Study , 2005, Cancer Epidemiology Biomarkers & Prevention.

[21]  A. Peri,et al.  Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[22]  B. Henderson,et al.  Association of an Exon 1 Polymorphism in the IGFBP3 Gene with Circulating IGFBP-3 Levels and Colorectal Cancer Risk: The Multiethnic Cohort Study , 2005, Cancer Epidemiology Biomarkers & Prevention.

[23]  Graham A. Colditz,et al.  The Nurses' Health Study: lifestyle and health among women , 2005, Nature Reviews Cancer.

[24]  S. Hankinson,et al.  Circulating Levels of Insulin-like Growth Factors, their Binding Proteins, and Breast Cancer Risk , 2005, Cancer Epidemiology Biomarkers & Prevention.

[25]  A. Ashworth,et al.  Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  W. Willett,et al.  Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era , 2005, Cancer Causes & Control.

[27]  X. Shu,et al.  Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[28]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[29]  M. Yaffe,et al.  A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  Brian Staats,et al.  SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes , 2004, Nucleic Acids Res..

[31]  J. Bertherat,et al.  Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. , 2003, The Journal of clinical endocrinology and metabolism.

[32]  D. Hunter,et al.  Polymorphic variation at the ‐202 locus in IGFBP3: Influence on serum levels of insulin‐like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk , 2003, International journal of cancer.

[33]  D. Albanes,et al.  Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. , 2003, Cancer research.

[34]  E. Rimm,et al.  Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[35]  N. Probst-Hensch,et al.  IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort , 2003, British Journal of Cancer.

[36]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[37]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[38]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[39]  M. Stampfer,et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[40]  S. Narod,et al.  Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  M. Stampfer,et al.  Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. , 2001, The Journal of clinical endocrinology and metabolism.

[42]  J. Gohagan,et al.  Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. , 2000, Controlled clinical trials.

[43]  D O Stram,et al.  A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. , 2000, American journal of epidemiology.

[44]  M. Thorén,et al.  Determinants of circulating insulin-like growth factor-I. , 1999, Journal of endocrinological investigation.

[45]  Stephen Twigg,et al.  Insulin-like Growth Factor (IGF)-binding Protein 5 Forms an Alternative Ternary Complex with IGFs and the Acid-labile Subunit* , 1998, The Journal of Biological Chemistry.

[46]  J. Kaprio,et al.  Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. , 1996, The Journal of clinical investigation.

[47]  P. Kao,et al.  Insulin-like growth factor-I comparisons in healthy twin children. , 1994, The Journal of clinical endocrinology and metabolism.

[48]  J. Ketelslegers,et al.  Nutritional regulation of the insulin-like growth factors. , 1994, Endocrine reviews.

[49]  J. Fraumeni,et al.  Design, Methods, Participant Characteristics, and Compliance , 1993 .

[50]  R. Baxter,et al.  Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. , 1990, The Journal of clinical endocrinology and metabolism.

[51]  E. Froesch,et al.  Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. , 1989, Acta endocrinologica.

[52]  R. Baxter,et al.  High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum. , 1989, The Journal of biological chemistry.

[53]  B. Rosner.  Percentage Points for a Generalized ESD Many-Outlier Procedure , 1983 .